← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Phoenix Nest, Inc.
Brooklyn, NY
$16,235,847
Total funding
8
Grants
Funding over time
peak $5.1M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,235,847 · 8
By mechanism
U44$5,612,276 · 1
R44$4,934,685 · 2
UB1$3,519,934 · 1
R42$1,495,008 · 1
R41$673,944 · 3
Investigators at Phoenix Nest, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development and validation of therapy for mucopolysaccharidosis III$3,176,406
U44 · FY2018 · NS
Development and Validation of Therapy for Mucopolysaccharidosis III$2,435,870
U44 · FY2022 · NS
Development of gene replacement therapy for Sanfilippo Syndrome Type C$1,495,610
R44 · FY2022 · NS
Development of Gene Replacement Therapy for Sanfilippo Syndrome Type C$1,494,895
R44 · FY2023 · NS
Evaluation of clinical outcome assessment (COA) and potential biomarkers to Facilitate Interventionaltrial for Mucopolysaccharidosis IIID Patients$1,125,627
UB1 · FY2022 · NS
Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients$1,125,625
UB1 · FY2023 · NS
Identification of Potential Biomarkers and Clinical Tools for use in Mucopolysaccharidosis IIIC Patients.$1,062,505
R44 · FY2025 · NS
Identification of Potential Biomarkers and Clinical Tools for use in Mucopolysaccharidosis IIIC Patients.$881,675
R44 · FY2024 · NS
Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients$798,341
UB1 · FY2024 · NS
Development and validation of therapy for mucopolysaccharidosis III$777,801
R42 · FY2017 · NS
Development and validation of therapy for mucopolysaccharidosis III$717,207
R42 · FY2016 · NS
Evaluation of clinical outcome assessment (COA) and potential biomarkers to Facilitate Interventionaltrial for Mucopolysaccharidosis IIID Patients$370,341
UB1 · FY2021 · NS
Structure-based optimization of a novel pharmacological chaperone therapy for MPSIIIC$224,873
R41 · FY2017 · HD
Engineering stem cells to make mucopolysaccharidosis IIIB$224,469
R41 · FY2016 · NS
Development and in vitro validation of therapy for mucopolysaccharidosis III$223,102
R41 · FY2014 · NS
Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients$100,000
UB1 · FY2024 · NS
Development and in vitro validation of therapy for mucopolysaccharidosis III$1,500
R41 · FY2015 · NS